MADRIGAL PHARMACEUTICALS, INC.

MDGL

CIK 0001157601 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$321M
↑+210.8% +$218Mvs FY2024 (Q4)
Gross Profit
$321M
↑+210.8% +$218Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Strong
70/100
  • Profitability
    0ROIC -26.1% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 4.01 (above 1.5 = solid)
  • Leverage
    72D/E 0.56 (under 0.5 = conservative)
  • Efficiency
    49Asset Turnover 0.83x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +210.8% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin -39.7% · trend +608.8pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$857K
investment in PP&E
Stock-based comp (TTM)
$98M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$1.26B
everything owned
Total liabilities
$657M
everything owed
Stockholders' equity
$603M
shareholder claim
Net debt
$141M
LT debt minus cash

Recent performance · 63 quarters

Revenue↑+210.8% +$218M
$321M
Net Income↓-6.8% -$7M
$-114M
Free Cash Flow↑+10240.3% +$80M
$79M
Operating Margin↑+147.4pts
-39.7%

Drill down